ERRATUM: Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group

Article information

Cancer Res Treat. 2023;55(3):1061-1061

Publication date (electronic) : 2023 April 21

doi : https://doi.org/10.4143/crt.2021.1115.E

¹Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

²Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

³Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

⁴Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

⁵Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

⁶Department of Genomic Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

⁷Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea

⁸Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, Daegu, Korea

⁹Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

¹⁰Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea

¹¹Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

¹²Division of Medical Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea

¹³Center for Colorectal Cancer, National Cancer Center, Research Institute and Hospital, Goyang, Korea

¹⁴Department of Internal Medicine, Hallym University Medical Center, Hallym University, Anyang, Korea

Correction to: Cancer Res Treat. 2022 Jan;54(1):1-9; DOI: https://doi.org/10.4143/crt.2021.1115

For the data represented in Table 2, we have corrected the level of evidence of K-CAT level 2 and 3. As the table shown, prospective phase I/II trials required for K-CAT level 2 include clinical trials across tumor types, such as basket trials. For the clinical benefit of specific cancer types, expert consensus is needed. K-CAT level 3A requires a retrospective study or case series with potential clinical benefit in s specific tumor types. K-CAT level 3B is revised from a retrospective study as clinical studies show potential clinical benefits in other indications. The corrected version of the table is below.

Table 2.

KPMNG scale of clinical actionability of molecular target (K-CAT)

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 2.

KPMNG scale of clinical actionability of molecular target (K-CAT)

Level	Clinical implication	Required level of evidence
1	Treatment should be considered standard of care	MFDS, FDA, EMA or equivalent-approved drug OR
1	Treatment should be considered standard of care	Prospective, randomized, phase III trials showing the benefit of survival endpoints
2	Treatment would be considered	Prospective phase I/II trials show clinical benefit^a)
3	Clinical trials to be discussed with patients	A: Retrospective study or case series show potential clinical benefit in a specific tumor type
3	Clinical trials to be discussed with patients	B: Clinical studies show potential clinical benefit in other indications
4	Preclinical data only, lack of clinical data	Preclinical evidence suggests the potential benefit
G	Suspicious germline variant on tumor tissue NGS	Suggestive actionable germline variant on tumor tissue testing
R	Predictive biomarker of resistance	FDA-recognized predictive biomarker of resistance

EMA, European Medicines Agency; FDA, U.S. Food and Drug Administration; K-CAT, KPMNG scale of Clinical Actionability of molecular Targets; KPMNG, Korean Precision Medicine Networking Group; MFDS, Ministry of Food and Drug Safety; NGS, next-generation sequencing.

^a)

Prospective phase I/II trials supporting level 2 targets include clinical trials across tumor types such as basket trials. In this case, the clinical benefit needs to be judged by expert consensus.